REFERENCE FORMULA
Reference formula
Reference basis: 100 mL
| Ingredient | Source quantity | Scaled quantity |
|---|---|---|
| Dexamethasone sodium phosphate | 132 mg | — |
| Preserved water without propylene glycol EX028 | 20 mL | — |
| Preserved simple syrup EX029 | q.s. ad 100 mL | — |
| Strawberry essence | 1 — όχι νεογνά / omit for neonates σταγόνα / drop | — |
Prerequisite formulations
Documentation
Preparation description
Colourless to pale yellow; pH 6.5–7.5. [1]
Action and use
Glucocorticoid. [1]
Specifications
Colourless to pale yellow; pH 6.5–7.5. [1]
Light
For the finished product the source specifies:
Well-closed amber glass bottle; 2–8 °C, protected from light. [1]
Well-closed amber glass bottle; 2–8 °C, protected from light. [1]
Air and oxidation
No oxidative stability study of the finished mixture or inert-atmosphere requirement is provided. Use the source container. [1]
Water and solubility
Component of base CGR-ES-003: Methyl Parahydroxybenzoate: JP classifies the corresponding pure raw material as slightly soluble in water.
Component of base CGR-ES-003: Propyl Parahydroxybenzoate: JP classifies the corresponding pure raw material as very slightly soluble in water.
Component of base CGR-ES-003: Sucrose: JP classifies the corresponding pure raw material as very soluble in water. [5], [6], [7], [8]
Component of base CGR-ES-003: Propyl Parahydroxybenzoate: JP classifies the corresponding pure raw material as very slightly soluble in water.
Component of base CGR-ES-003: Sucrose: JP classifies the corresponding pure raw material as very soluble in water. [5], [6], [7], [8]
Humidity
No numerical relative-humidity limit is given for the finished product. Prevent raw-material wetting and condensation entering the container. [1]
Temperature
For the finished product the source specifies:
Well-closed amber glass bottle; 2–8 °C, protected from light. [1]
Well-closed amber glass bottle; 2–8 °C, protected from light. [1]
pH and compatibility
Specification of this preparation, not a demonstrated stability range:
Colourless to pale yellow; pH 6.5–7.5. [1]
Colourless to pale yellow; pH 6.5–7.5. [1]
Other interactions
No complete compatibility test with added actives or alternative excipients is provided. Substitutions require separate evidence. [1]
Ingredient-specific information
Identity and weighing basis:
• Dexamethasone sodium phosphate: 132 mg.
• Preserved water without propylene glycol EX028: 20 mL.
• Preserved simple syrup EX029: q.s. ad 100 mL.
The specified chemical forms/grades belong to the exact source formula.
Component of base CGR-ES-003: Methyl Parahydroxybenzoate: raw-material water solubility is classified as slightly soluble by JP.
Component of base CGR-ES-003: Propyl Parahydroxybenzoate: raw-material water solubility is classified as very slightly soluble by JP.
Component of base CGR-ES-003: Sucrose: raw-material water solubility is classified as very soluble by JP. [1], [5], [6], [7], [8]
• Dexamethasone sodium phosphate: 132 mg.
• Preserved water without propylene glycol EX028: 20 mL.
• Preserved simple syrup EX029: q.s. ad 100 mL.
The specified chemical forms/grades belong to the exact source formula.
Component of base CGR-ES-003: Methyl Parahydroxybenzoate: raw-material water solubility is classified as slightly soluble by JP.
Component of base CGR-ES-003: Propyl Parahydroxybenzoate: raw-material water solubility is classified as very slightly soluble by JP.
Component of base CGR-ES-003: Sucrose: raw-material water solubility is classified as very soluble by JP. [1], [5], [6], [7], [8]
Staff protection
Risk assessment
Reference batch: 100 mL. First ingredient: Dexamethasone sodium phosphate, 132 mg. Independently check chemical form, units and every scale conversion before weighing.
Check complete dissolution and crystallisation at the selected temperature. Calculate dose volume from the exact mg/mL, not the starting tablet or stock strength. Supply a suitable oral syringe.
For the local assessment record quantity per preparation, work frequency, duration of open handling, potential exposure routes and effectiveness of controls. These are assessment inputs; no fictitious final risk score is assigned.
Release checkpoint: confirm final volume or mass at the reference temperature, intended clarity or dispersion, and specified container/closure. Do not equate grams and millilitres without a justified density. [1], [10], [12]
Check complete dissolution and crystallisation at the selected temperature. Calculate dose volume from the exact mg/mL, not the starting tablet or stock strength. Supply a suitable oral syringe.
For the local assessment record quantity per preparation, work frequency, duration of open handling, potential exposure routes and effectiveness of controls. These are assessment inputs; no fictitious final risk score is assigned.
Release checkpoint: confirm final volume or mass at the reference temperature, intended clarity or dispersion, and specified container/closure. Do not equate grams and millilitres without a justified density. [1], [10], [12]
Compounding conditions
BUD rationale
Period reported by source: 60 days at 2–8 °C; after opening 30 days, within overall expiry.
This duration is a specific formulary/source instruction. This review did not verify a complete primary study establishing chemical, physical and microbiological extension for the same finished formulation.
Selected general rule: up to 35 days for an aqueous form appropriately preserved in its final composition and pH. Use 20–25 °C, or 2–8 °C only where permitted/required by the source and compatible with the dosage form. A preservative name is insufficient if it is diluted, inactivated or partitioned into another phase.
The reference-policy ceiling in this edition is the shorter of the source period above and the general ceiling. Extension needs matching active/excipients/strength, container, temperature, a stability-indicating method and the required microbiological evidence for aqueous extension. An applicable official USP–NF compounded monograph is assessed separately in its complete text.
Use-by date = the earliest allowed date from preparation plus selected period, ingredient expiries and any shorter supported limit. In-use dating never extends overall BUD. Complete the actual date for the batch after the required checks.
A default is a conservative dating limit, not experimental proof of batch stability. Its category depends on final composition, preservation and permitted temperatures. Water percentage or loss on drying does not determine aw. Document using SOP-014/F-006; use SOP-017/F-012 for specific aw evidence.
USP does not require water-activity measurement for every nonsterile preparation. A justified classification of the actual formulation may guide dating; record it explicitly as inferred, not measured. Uncertain or borderline classification requires specific evidence or a suitable measurement. Finished-product dating does not outlast the available dating of previously compounded components/bases unless adequate specific evidence for the exact finished preparation has been formally adopted. [1], [4], [9], [11], [14]
This duration is a specific formulary/source instruction. This review did not verify a complete primary study establishing chemical, physical and microbiological extension for the same finished formulation.
Selected general rule: up to 35 days for an aqueous form appropriately preserved in its final composition and pH. Use 20–25 °C, or 2–8 °C only where permitted/required by the source and compatible with the dosage form. A preservative name is insufficient if it is diluted, inactivated or partitioned into another phase.
The reference-policy ceiling in this edition is the shorter of the source period above and the general ceiling. Extension needs matching active/excipients/strength, container, temperature, a stability-indicating method and the required microbiological evidence for aqueous extension. An applicable official USP–NF compounded monograph is assessed separately in its complete text.
Use-by date = the earliest allowed date from preparation plus selected period, ingredient expiries and any shorter supported limit. In-use dating never extends overall BUD. Complete the actual date for the batch after the required checks.
A default is a conservative dating limit, not experimental proof of batch stability. Its category depends on final composition, preservation and permitted temperatures. Water percentage or loss on drying does not determine aw. Document using SOP-014/F-006; use SOP-017/F-012 for specific aw evidence.
USP does not require water-activity measurement for every nonsterile preparation. A justified classification of the actual formulation may guide dating; record it explicitly as inferred, not measured. Uncertain or borderline classification requires specific evidence or a suitable measurement. Finished-product dating does not outlast the available dating of previously compounded components/bases unless adequate specific evidence for the exact finished preparation has been formally adopted. [1], [4], [9], [11], [14]
Prerequisites
Preserved water without propylene glycol AEMPS: CGR-ES-002
Preserved syrup 84% w/v AEMPS: CGR-ES-003
A resolved and released EX029 / CGR-ES-003 base is required. [1]
Preserved syrup 84% w/v AEMPS: CGR-ES-003
A resolved and released EX029 / CGR-ES-003 base is required. [1]
Equipment
Balance with suitable minimum weight, mortar/pestle or homogeniser, mixing vessels, spatulas, thermometer for heated processes and volumetric equipment for mL quantities.
Calibrated pH meter and suitable check buffers. [1]
Calibrated pH meter and suitable check buffers. [1]
Compounding method
Dissolve sodium phosphate in EX028, make up with EX029 and homogenise. Add flavour only where permitted; check pH. [1]
Observations
Prepare base CGR-ES-003 using the exact published ratios and a theoretical 1000.75 g input basis. Use the required quantity only after density and pH checks. The finished preparation retains its own preservation, packaging and BUD assessment. [13]
Container and packaging
Well-closed amber glass bottle; 2–8 °C, protected from light. [1]
Quality control
Storage
Well-closed amber glass bottle; 2–8 °C, protected from light. [1]
Dispensing
Dispense the exact prescribed strength. For liquids use a suitable graduated oral syringe; record dose and frequency from the prescription. [1]
Labelling
Dexamethasone Oral Solution 1 mg/mL
Oral use
Quantity: ____ Batch: ____
Prepared: ____ Use by: ____
Patient / dose / frequency: ____
Storage: Well-closed amber glass bottle; 2–8 °C, protected from light.
Temperature for this batch BUD: ____ [1]
Oral use
Quantity: ____ Batch: ____
Prepared: ____ Use by: ____
Patient / dose / frequency: ____
Storage: Well-closed amber glass bottle; 2–8 °C, protected from light.
Temperature for this batch BUD: ____ [1]
v9_controls
The numeric value is a literature reference ceiling subject to its specific conditions. No actual batch BUD has been assigned and no aw measurements have been produced. The exact formula, prerequisites, container, storage and quality evidence require approval for the actual application. The BUD clock starts when compounding begins. Use the shortest applicable supported limit and assess in-use dating separately. USP categories are a technical framework and are not presented as Greek legislation.
Independent Greek/English adaptation and organisation of facts from the cited source. This is not an official translation or publisher endorsement.
Sources and references
- FN/2020/FMT/030 DEXAMETASONA 1 MG/ML SOLUCIÓN ORAL2020PDF pp. 2master formula2026-09-10
- PN/L/PG/002/00 INDUMENTARIAΔιαθέσιμο κείμενο / Retrieved textPDF pp. 1–5general staff protection2026-09-10
- ASHP — USP <795> Key Changes2023pp. 1–3: scope, water activity and staff precautionsprofessional guidance; not the licensed USP chapter2026-09-12
- Texas State Board of Pharmacy — adopted 22 TAC §291.131, nonsterile compoundingTexas Register, 7 June 2024Beyond-use dating: aw categories, 14/35/90/180 days, limits and extensionspublic regulatory implementation of USP <795> BUD framework; not Greek law2026-09-12
- MHLW — Japanese Pharmacopoeia XVIII: Methyl ParahydroxybenzoateJP XVIII, 2021; English textPrinted p. 1343; Description; Containers and storageraw-material monograph2026-09-12
- FN/2019/EX/029 JARABE SIMPLE (84% P/V) CON CONSERVANTE2019PDF pp. 1–2master formula2026-09-10
- MHLW — Japanese Pharmacopoeia XVIII: Propyl ParahydroxybenzoateJP XVIII, 2021; English textPrinted p. 1601; Description; Containers and storageraw-material monograph2026-09-12
- MHLW — Japanese Pharmacopoeia XVIII: SucroseJP XVIII, 2021; English textPrinted p. 1748; Description; Containers and storageraw-material monograph2026-09-12
- Illinois IDFPR — Nonsterile Compounding Self-Inspection ReportPublic checklist, retrieved 12 September 2026pp. 15–16, Establishing beyond-use datesPublic regulatory implementation of USP <795>; not Greek law; general limits and requirements for extension2026-09-12
- NIOSH — Managing Hazardous Drug Exposures: Information for Healthcare Settings2023; DHHS (NIOSH) 2023-130Risk assessment; printed pp. 27–33, activity/formulation control tableWorkplace exposure, hierarchy of controls and activity-specific PPE; US government public-domain document2026-09-12
- USP — Compounding Standards and Beyond-Use Dates, 2022 updateNovember 2022, published by USP; public copy hosted by Mississippi Boardpp. 1–2; nonsterile tableRisk-based default categories; not product-specific stability or Greek law2026-09-12
- PIC/S — Guide to Good Practices for the Preparation of Medicinal Products in Healthcare EstablishmentsPE 010-4, 1 March 2014Chapters 1–9; Annex 2 (nonsterile liquids, creams, ointments)Professional quality-system framework; not automatic national legal adoption or certification2026-09-12
- SEFH — Manual de Farmacotecnia2023p. 71, Table 2; p. 177 preservatives; p. 302 microbiologyProfessional society manual: corroborates EX029 listed ingredient masses; not an AEMPS erratum or stability experiment2026-09-12
- USP — General Chapter <795> FAQs (official, updated 1 November 2023)Updated 1 November 2023; retrieved 14 October 2026Q52, Q61–64; use with the applicable full chapterWater-activity classification, component dating and BUD documentation; general professional framework, not a Greek legal adoption or formula-specific study2026-10-14